Abstract:Aging is a major risk factor in amyotrophic lateral sclerosis (ALS) and other adult-onset neurodegenerative disorders. Whereas young neurons are capable of buffering disease-causing stresses, mature neurons lose this ability and degenerate over time. We hypothesized that the resilience of young motor neurons could be restored by re-expression of the embryonic motor neuron selector transcription factors ISL1 and LHX3. We found that viral re-expression of ISL1 and LHX3 reactivates aspects of the youthful gene expression program in mature motor neurons and alleviates key disease-relevant phenotypes in the SOD1 mouse model of ALS. Our results suggest that redeployment of lineage-specific neuronal selector transcription factors can be an effective strategy to attenuate age-dependent phenotypes in neurodegenerative disease.

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve This paper aims to address the degeneration of mature motor neurons in Amyotrophic Lateral Sclerosis (ALS). Specifically, the researchers hypothesize that by re-expressing the embryonic motor neuron-selective transcription factors ISL1 and LHX3, they can reactivate the youthful gene expression program in mature motor neurons, thereby enhancing these neurons' resistance to disease-related stress and delaying or preventing the pathological features of ALS. ### Background and Motivation 1. **Relationship between Age and ALS**: - Age is a major risk factor for ALS and other adult-onset neurodegenerative diseases. Young neurons can buffer against disease-causing stress, whereas mature neurons gradually lose this ability and eventually degenerate. 2. **Changes in Gene Expression**: - During maturation, motor neurons undergo significant changes in gene expression and chromatin accessibility, making it very difficult to identify which genes or genomic regions are responsible for the susceptibility of mature neurons to degeneration. 3. **Role of ISL1 and LHX3**: - ISL1 and LHX3 are two key transcriptional activators that are highly expressed in newborn motor neurons but are downregulated after maturation. These factors play a crucial role in the specialization of spinal motor neurons and can reprogram neural precursor cells, pluripotent stem cells, and adult skin fibroblasts into immature spinal motor neurons. ### Research Methods 1. **Virus-Mediated Gene Expression**: - Researchers used adeno-associated virus (AAV) vectors to specifically re-express ISL1 and LHX3 in spinal motor neurons. 2. **Experimental Animal Model**: - The SOD1G93A transgenic mouse model was used to evaluate the effects of re-expressing ISL1 and LHX3. This model can mimic many biochemical and behavioral features of ALS, including defects in protein misfolding handling, neuromuscular junction degeneration, motor neuron degeneration, neuroinflammation, and rapid progression of clinical symptoms. ### Main Findings 1. **Changes in Gene Expression and Chromatin Accessibility**: - Re-expressing ISL1 and LHX3 can reactivate the youthful gene expression program in mature motor neurons and alter chromatin accessibility. These changes are mainly concentrated in α-type and type 3 motor neurons, with weaker effects in γ-type motor neurons. 2. **Improvement in Pathological Features**: - Re-expressing ISL1 and LHX3 significantly reduces the formation of SQSTM1-positive protein aggregates, which are one of the early pathological features of ALS. Additionally, re-expressing ISL1 and LHX3 reduces the formation of mutant SOD1 protein aggregates, which are key factors in the progression of ALS. 3. **Delay in Clinical Symptoms**: - In the SOD1G93A mouse model, re-expressing ISL1 and LHX3 significantly delays the onset of clinical symptoms, particularly delaying the tremor symptoms in female mice from P90 to P105. ### Conclusion This study preliminarily demonstrates that re-expressing ISL1 and LHX3 can restore a youthful gene expression state in mature motor neurons, enhance their ability to resist disease-related stress, and delay the appearance of ALS pathological features and clinical symptoms. This strategy provides new insights for developing highly targeted reprogramming methods for specific susceptible neuron types to inhibit adult-onset neurodegenerative diseases.

Embryonic motor neuron programming factors reactivate immature gene expression and suppress ALS pathologies in postnatal motor neurons

Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice.

Temporal response of neural progenitor cells to disease onset and progression in amyotrophic lateral sclerosis-like transgenic mice.

Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis

Transcriptional modulation unique to vulnerable motor neurons predicts ALS across species and SOD1 mutations

Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs

LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice

Integrated temporal profiling of iPSCs-derived motor neurons from ALS patients carrying C9orf72, FUS, TARDBP, and SOD1 mutations

ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation

Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection

In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model

Human Motor Neurons Elicit Pathological Hallmarks of ALS and Reveal Potential Biomarkers of the Disease in Response to Prolonged IFNγ Exposure

Motoneuron Differentiation of Induced Pluripotent Stem Cells from Sod1g93a Mice

ALS, a cellular whodunit on motor neuron degeneration

Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies

Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders

Neuromuscular dysfunction in patient-derived FUS -ALS iPSC model via axonal downregulation of neuromuscular junction proteins

CREB3 gain of function variants protect against ALS

Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons

An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of amyotrophic lateral sclerosis

Distinct transcriptomic profile of satellite cells contributes to preservation of neuromuscular junctions in extraocular muscles of ALS mice